Physicochemical Properties
| Molecular Formula | C121H213F3N46O28 |
| Molecular Weight | 2817.27 |
| Related CAS # | TAT-Gap19;1507930-54-2 |
| Appearance | White to off-white solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo | In 4-month-old C57Bl6 male mice, a single intravenous injection of TAT-Gap19 TFA (iv; 55 mg/kg) results in a notable immunological signal in the brain 24 hours later[1]. Mice treated with 100–200 mg thioacetamide (TAA)/kg body weight for eight weeks[2] showed dramatically reduced collagen deposition and lowed levels of α-SMA-positive cell area when given TAT-Gap19 TFA (1 mg/kg /day) via an osmotic pump implanted in the peritoneal cavity. |
| References |
[1]. The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front Cell Neurosci. 2014 Oct 21;8:306. [2]. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018 Mar 12;19(3):817. [3]. Inhibition of astroglial connexin43 hemichannels with TAT-Gap19 exerts anticonvulsant effects in rodents. Glia. 2018 Aug;66(8):1788-1804. |
Solubility Data
| Solubility (In Vitro) | H2O :~100 mg/mL (~35.50 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (35.50 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3550 mL | 1.7748 mL | 3.5495 mL | |
| 5 mM | 0.0710 mL | 0.3550 mL | 0.7099 mL | |
| 10 mM | 0.0355 mL | 0.1775 mL | 0.3550 mL |